Not intended for UK and US audiences JASCAYD® (nerandomilast) is the first oral, preferential PDE4B inhibitor approved in the European Union, ...

Researchers at Tulane University have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly and currently incurable lung disease that affects more than 3 million people ...

Pulmonary fibrosis is a deadly disease in which scar tissue grows in the lungs, making breathing more difficult.

A new Mayo Clinic study shows that integrating telomere length evaluation and genetic testing into pulmonary care can significantly change how physicians diagnose and treat pulmonary fibrosis - in ...

Pulmonary fibrosis is a deadly disease where scar tissue grows in the lungs, making breathing more difficult. Approximately 2 ...

A new drug for pulmonary fibrosis has reduced disease progression by more than 50% over a 52-week treatment in two clinical trials. Pulmonary fibrosis is a very serious disease, with a life prognosis ...

IPF is a chronic lung disease with fibrous tissue formation, leading to respiratory decline and poor prognosis, affecting mainly older adults. Diagnosis is challenging due to its exclusionary nature, ...

Researchers from UTS and Monash University have identified vitronectin as a key protein driving abnormal lung scarring in ...

Idiopathic pulmonary fibrosis stands as one of medicine’s most challenging respiratory conditions, gradually transforming healthy lung tissue into stiff, scarred material that severely compromises ...

India, July 18 -- Collaborative innovation aims to strengthen early disease monitoring, clinical decision-making, and remote respiratory care Sehore : Researchers at VIT Bhopal University and ...

Panelists discuss how idiopathic pulmonary fibrosis (IPF), a progressive and often fatal interstitial lung disease, presents significant clinical challenges due to its variable trajectory, limited ...